Nanobiotix - ADR Stock News

PARIS and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced advancements for its next-wave Curadigm Nanoprimer platform.

PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

PARIS and CAMBRIDGE, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that it has entered into a royalty-based financing agreement with HealthCare Royalty (“HCRx...

Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1 st

PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month ...

Data presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th

Nanobiotix S.A. stock has surged after strong Phase 1 data for NBTXR3 in anti-PD-1 resistant melanoma, showing high response and disease control rates. NBTX's partnership with Janssen could yield up to $2.6bn in milestones, crucial for funding late-stage trials and extending financial runway. Upcoming catalysts include Phase 3 head and neck cancer data and NSCLC trial progress, with a $10bn mar...

Nanobiotix S.A. - Special Call Company Participants Joanne Choi Laurent Levy - Co-Founder, President of the Executive Board & CEO Conference Call Participants Ruoxi Liao - Guggenheim Securities, LLC, Research Division Clemence Thiers - Stifel, Nicolaus & Company, Incorporated, Research Division Swayampakula Ramakanth - H.C.